Drug Profile
F 598
Alternative Names: Anti-PNAG-monoclonal-antibody; Anti-poly-N-acetyl-glucosamine-monoclonal-antibody; F598; SAR279356Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Alopexx Pharmaceuticals
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Surface antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Bacterial infections
- Phase I Postoperative infections
- No development reported Gonorrhoea; Tuberculosis
Most Recent Events
- 12 Oct 2023 Pharmacodynamics data from a preclinical study in non-viral microbial infections released by Aloplexx Pharmaceuticals
- 05 Jul 2022 F 598 is still in phase II trials for Bacterial infections (Prevention) in intensive care unit (ICU) patients in USA (Aloplexx pipeline, July 2022)
- 05 Jul 2022 No development reported - Phase-II for Gonorrhoea (Prevention) in USA (IV) (Aloplexx pipeline, July 2022)